Vizsgálati helyszín
Haifa
Haifa, 3109601, IzraelMég nincs intézményhez kötve
- 16futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Toboroz7 vizsgálat
- Lezárult3 vizsgálat
- Fő szponzor
- GlaxoSmithKline15 vizsgálat
- Tesaro, Inc.3 vizsgálat
- ViiV Healthcare1 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT07286331· 3. fázis· GlaxoSmithKline· Forrás
Contact: Emad Matanes (principal investigator)
Toboroz
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· 2. fázis· GlaxoSmithKline· Forrás
Contact: Michal Shteinberg (principal investigator)
Toboroz
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· 3. fázis· GlaxoSmithKline· Forrás
Contact: Yochai Adir (principal investigator)
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· 3. fázis· GlaxoSmithKline· Forrás
Contact: Emilia Hardak (principal investigator)
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Contact: Salem Billan (principal investigator)
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· 3. fázis· ViiV Healthcare· Forrás
Toboroz
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· 2/3. fázis· GlaxoSmithKline· Forrás
Contact: Devy Zisman (principal investigator)
Fut, nem toboroz
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247· 2. fázis· GlaxoSmithKline· Forrás
Contact: Amnon Amit (principal investigator)
Fut, nem toboroz
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· 3. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· 3. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· 3. fázis· Tesaro, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek